In the phase 3 DREAM3R trial (NCT04334759, ACTRN12620001199909), first-line durvalumab (Imfinzi) plus chemotherapy demonstrated consistent overall survival (OS), progression-free survival (PFS), and objective response rates (ORR)benefits in…
Category: 6. Business
-
Evaluating Helios Technologies (HLIO) Valuation as Demand and Operational Gains Drive Investor Optimism
Helios Technologies (NYSE:HLIO) shares climbed higher after the company saw increased demand from its industrial and health & wellness segments. This growth was fueled by strong sales of its quick-release coupling products and effective cost…
Continue Reading
-
Failure to Deliver Silver Will Create Contagion
Failure to Deliver Silver Will Create Contagion | The Jerusalem PostJerusalem Post/Business & Innovation/Precious MetalsA looming silver shortage threatens the global financial system as paper contracts fail. When metal can’t be delivered,…
Continue Reading
-
Silver Supply Struggles to Keep Up as Demand Skyrockets
Silver Supply Struggles to Keep Up as Demand Skyrockets | The Jerusalem PostJerusalem Post/Business & Innovation/Precious MetalsSilver demand is skyrocketing, overwhelming sellers and disrupting markets worldwide. Scottsdale Mint CEO Josh Phair…
Continue Reading
-
Subgroup Analysis Yields Clinically Meaningful Responses With T-DXd in HER2+ Breast Cancer
A clinically meaningful progression-free survival benefit (PFS) was observed with fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) plus pertuzumab (Perjeta), despite prior treatment, hormone receptor status, or PIK3CA mutations, when compared…
Continue Reading
-
Highland rail line closes as £4.5m upgrade begins
A railway line in the west Highlands has been closed to allow for £4.5m worth of upgrades to be carried out over the coming weeks.
The Kyle line stretches more than 50 miles (80km) from Inverness to Kyle of Lochalsh.
Around 4.5 miles (7km) of…
Continue Reading
-
Adjuvant Therapy Confers Postoperative ctDNA Clearance, DFS Benefit in CRC
Adjuvant therapy can feasibly yield circulating tumor DNA (ctDNA) clearance in a portion of patients with colorectal cancer (CRC) and postoperative ctDNA positivity, with clearance correlating with superior disease-free survival (DFS) outcomes,…
Continue Reading
-
Final Analysis of COMPASSION-15 Presented at ESMO 2025
HONG KONG, Oct. 19, 2025 /PRNewswire/ — On October 19, 2025, Akeso (9926.HK) announced the final analysis results from the COMPASSION-15/AK104-302 study at the 2025 European…
Continue Reading
-
212Pb-DOTAMTATE Shows Impressive Antitumor Activity in Previously Treated GEP-NETS | Targeted Oncology
212Pb-DOTAMTATE (AlphaMedix) showed clinically meaningful antitumor activity with sustained and durable responses along with a manageable safety profile in patients with peptide receptor radionuclide therapy (PRRT)-exposed, somatostatin receptor…
Continue Reading
-
Capivasertib Combo Extends rPFS in PTEN-Deficient HSPC | Targeted Oncology
Findings from the CAPItello-281 trial (NCT04493853) presented at the 2025 European Society for Medical Oncology (ESMO) Congress showed that the combination of the oral AKT inhibitor capivasertib (Truqap) plus abiraterone acetate, prednisone, and…
Continue Reading